Senaste uppdateringen :
14/12/2024
cancerläkemedel   Vinorelbine tartrate  
injektion
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Eberelbin Iran
Eunexon Peru
Eurovinorelbin Tyskland
Navelbin Ungern
Navelbine Argentina, Australien, Belgien, Chile, Colombia, Danmark, Egypten, Finland, Förenade Arabemiraten, Förenta Staterna, Frankrike, Grekland, Indien, Iran, Irland, Island, Italien, Luxemburg, Malaysia, Mexiko, Norge, nya Zeeland, Österrike, Peru, Polen, Portugal, Rumänien, Saudi-Arabien, Schweiz, Spanien, Storbritannien, Sverige, Tunisien, Turkiet, Tyskland
Navildez Mexiko
Navin Tyskland
Navirel Norge, Sverige, Tyskland
Okabine Peru
Relbinalur Sverige
Renovel Turkiet
Setroxin Mexiko
Sulcoline Argentina
Tarckorel Mexiko, Peru
Vieby Mexiko
Viessia Colombia, Mexiko, Venezuela
Vilne Argentina, Ecuador, Peru
Vinarine Argentina, Peru, Venezuela
Vinelbine Malaysia
Vinilex Mexiko
Vinkebir Argentina, Peru
Vinobina Colombia
Vinobur Sverige
Vinolbin Tyskland
Vinorel Argentina, Peru
Vinorelbin Belgien, Ecuador, Island, Norge, Österrike, Rumänien, Schweiz, Sverige, Tyskland
Vinorelbina Colombia, Ecuador, Mexiko, Peru, Rumänien, Spanien
Vinorelbine Argentina, Belgien, Förenta Staterna, Iran, Kanada, nya Zeeland, Schweiz, Storbritannien
Vinorgen Chile, Peru
Zinavin Colombia
Hänvisningar   injektion   Hänvisningar : Vinorelbine tartrate  
Typ Publikation
84 tidningen Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
144 tidningen Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
182 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 tidningen Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
251 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 tidningen Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
905 tidningen Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 tidningen Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1070 tidningen Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891.
1413 tidningen Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68.
1423 tidningen Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1501 tidningen Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratorium Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 tidningen Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 tidningen Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
2260 Laboratorium Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3128 Laboratorium Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3474 Laboratorium Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3595 Laboratorium Aciclovir - Summary of Product Characteristics
Hospira 2009
3641 Laboratorium Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011
3644 Laboratorium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3838 Laboratorium Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4471 Laboratorium Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019

  Mentions Légales